Mesenchymal stem cells (MSC) hold significant promise for tissue engineering and regenerative medicine. The use of MSCs for translational research requires their expansion in GMP-grade media and, depending on the application, GMP-grade cytokines and growth factors. GMP-grade media and proteins are manufactured so that all products, materials, equipment, and processes used in production are traceable and controlled. This extra level of traceability is important and necessary for transitioning MSC research into a translational, FDA-approved therapy.
Our StemXVivo® GMP Mesenchymal Stem Cell Expansion Media is the same formulation as our StemXVivo® Mesenchymal Expansion Media (Catalog # CCM004), but is produced according to relevant sections of the following documents: WHO TRS, No. 822, 1992 Annex 1, Good Manufacturing Practices for Biological Products; USP Chapter 1043, Ancillary Materials for Cell, Gene and Tissue Engineered Products and USP Chapter 92, Growth Factors and Cytokines Used in Cell Therapy Manufacturing.
StemXVivo® GMP Mesenchymal Stem Cell Expansion Media is supplied in a 250 mL volume and contains high quality factors to support MSC expansion in vitro. Contains fetal bovine serum.
Stability and Storage
Store unopened reagents in the dark at < -20 °C in a manual defrost freezer. Do not use past the expiration date.
When handling biohazardous materials such as human cells, safe laboratory procedures should be followed and protective clothing should be worn.
View Larger Image
Figure 1: Phenotypic Analysis of Human MSCs Expanded in MSC Expansion Media. Human MSCs were expanded using StemXVivo® GMP MSC Expansion Media. Filled histograms indicate cells stained with markers of undifferentiated MSCs including anti-CD105 (R&D Systems, Catalog # FAB1097A), anti-CD73 (R&D Systems, Catalog # FAB5795P), anti-CD90 (R&D Systems, Catalog # FAB2067A), or anti-CD45 (R&D Systems, Catalog # FAB1430P). The open histograms show isotype-matched control staining. MSCs appropriately express high levels of CD105, CD73, and CD90, and lack expression of CD45.
R&D Systems' GMP media is produced according to relevant sections of the following documents: WHO TRS, No. 822, 1992 Annex 1, Good Manufacturing Practices for Biological Products; USP Chapter 1043, Ancillary Materials for Cell, Gene and Tissue Engineered Products and USP Chapter 92, Growth Factors and Cytokines Used in Cell Therapy Manufacturing.
R&D Systems' quality focus includes:
Additional testing and documentation requested by the customer can be arranged at an additional cost.
Production records and facilities are available for examination by appropriate personnel on site at R&D Systems in Minneapolis, Minnesota USA. R&D Systems sells its GMP grade media products for research use or further manufacturing use in ex vivo cell therapy applications. They are not for in vivo use or for use as therapeutic or other drugs, biologic products or devices. Please read the following End User Terms prior to using this product.
The End User is aware that R&D Systems, Inc. sells its GMP products for research use only or further manufacturing and not for in vivo use, the production of therapeutics or other drugs or for biologic products or devices. The End User further agrees, as a condition of the sale of R&D Systems' GMP products that: a) the End User will not use this GMP Product in any procedure wherein the product may be directly or indirectly administered to humans, unless the End User has obtained, or prior to their use will have obtained, an Investigational New Drug (IND) exemption from the FDA and will use the product only in accordance with the protocols of such IND and of the Institutional Review Board overseeing the proposed research, or b) the End User will use the products outside of the United States in accordance with the protocols of research approved by the Institutional Review Board or authorized ethics committee and regulatory agencies to which the End User is subject to in their territory.
Refer to the product datasheet for complete product details.
This protocol has been tested using bone marrow-derived MSCs. If using a different tissue source or cell line, the protocol below may need to be modified.
StemXVivo® GMP Mesenchymal Stem Cell Expansion Media - Thaw the MSC Expansion Media at 2-8 °C or room temperature.
Completed StemXVivo® GMP MSC Expansion Media - Add Penicillin-Streptomycin (100X) to the StemXVivo® GMP MSC Expansion Media at a 1:100 dilution. Note: If Penicillin-Streptomycin is not needed for the experiment, it can be omitted.
Trypsin-EDTA (1X) - Dilute Trypsin-EDTA (10X) to 1X using PBS.
Add 3.5 - 4.0 x 105 MSCs resuspended in 20 mL of the pre-warmed StemXVivo® GMP MSC Expansion Media to a T75 flask.
Replace the medium every 3 days with fresh Complete StemXVivo® GMP MSC Expansion Media.
Culture the MSCs to 80-90% confluency.
Remove and discard the media from the T75 tissue culture flask(s) containing the MSCs.
Wash the cells with PBS.
Add 1-2 mL of pre-warmed Trypsin-EDTA to the MSCs and incubate the flask at 37 °C.
Add 5mL of Complete StemXVivo® GMP MSC Expansion Media to the flask to neutralize the Trypsin-EDTA.
Transfer the dissociated MSCs to a 15 mL conical tube.
Centrifuge at 400 x g for 5 minutes.
Resuspend the cell pellet in 5 mL of StemXVivo® GMP MSC Expansion Media.
Perform a cell count.
Add 3.5-4.0 x 105 MSCs resuspended in 20 mL of pre-warmed Complete StemXVivo® GMP MSC Expansion Media to each T75 flask.
No product specific FAQs exist for this product, however you mayView all Cell Culture Product FAQs